» Articles » PMID: 40004829

Non-Criteria Obstetric Antiphospholipid Syndrome: Myth or Reality?

Overview
Journal J Clin Med
Specialty General Medicine
Date 2025 Feb 26
PMID 40004829
Authors
Affiliations
Soon will be listed here.
Abstract

Women with adverse pregnancy outcomes suggestive of obstetric antiphospholipid syndrome (OAPS), but not fulfilling clinical and/or laboratory international classification criteria, are increasingly recognized both in clinical practice and in the literature. This entity is termed non-criteria OAPS (NC-OAPS). It includes clinical scenarios such as two unexplained pregnancy losses, three non-consecutive pregnancy losses, late pre-eclampsia/eclampsia/signs of placental insufficiency, or recurrent implantation failure, as well as positive low-titers of antiphospholipid antibodies (aPLs) and non-classical aPLs. To address the NC-OAPS heterogeneity, a nomenclature proposal was developed. In recent years, retrospective and prospective cohort studies have been designed to clarify the characteristics and outcomes of the different subsets of NC-OAPS. In general, the studies support that NC-OAPS may benefit from treatment with antithrombotic, anticoagulant and/or immunomodulator agents, but several considerations must be made on the robustness and nuances of the scientific evidence. The objective of this review is to critically analyze the available evidence supporting the diagnosis of NC-OAPS, categorize its subsets, and evaluate the impact of treatment strategies on its outcome. We also remark on questions that are still unanswered, such as the lack of consensus on diagnostic criteria or treatment protocols.

References
1.
de Jesus G, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A . Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study. BJOG. 2018; 126(5):656-661. PMC: 7382947. DOI: 10.1111/1471-0528.15469. View

2.
Miyakis S, Lockshin M, Atsumi T, Branch D, Brey R, Cervera R . International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306. DOI: 10.1111/j.1538-7836.2006.01753.x. View

3.
Lefevre G, Lambert M, Bacri J, Dubucquoi S, Quemeneur T, Caron C . Thrombotic events during long-term follow-up of obstetric antiphospholipid syndrome patients. Lupus. 2011; 20(8):861-5. DOI: 10.1177/0961203310397080. View

4.
Wu L, Fang X, Lu F, Zhang Y, Wang Y, Kwak-Kim J . Anticardiolipin and/or anti-β2-glycoprotein-I antibodies are associated with adverse IVF outcomes. Front Immunol. 2022; 13:986893. PMC: 9667022. DOI: 10.3389/fimmu.2022.986893. View

5.
Mekinian A, Bourrienne M, Carbillon L, Benbara A, Noemie A, Chollet-Martin S . Non-conventional antiphospholipid antibodies in patients with clinical obstetrical APS: Prevalence and treatment efficacy in pregnancies. Semin Arthritis Rheum. 2016; 46(2):232-237. DOI: 10.1016/j.semarthrit.2016.05.006. View